FRANK S HODI

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901
    John D Roberts
    Virginia Commonwealth University, Richmond, Virgina 23298 0037, USA
    J Immunother 29:95-101. 2006
  2. ncbi request reprint Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage
    F Stephen Hodi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:673-8. 2006
  3. ncbi request reprint Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1857-67. 2007
  4. ncbi request reprint Cytotoxic T-lymphocyte-associated antigen-4
    F Stephen Hodi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5238-42. 2007
  5. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008
  6. doi request reprint Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways
    XinQi Wu
    Department of Medical Oncology, Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 11:1905-14. 2012
  7. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  8. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  9. pmc Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
    Jun Zhou
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Immunol Immunother 61:655-65. 2012
  10. doi request reprint CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
    F Stephen Hodi
    Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Nat Clin Pract Oncol 5:557-61. 2008

Research Grants

Detail Information

Publications38

  1. ncbi request reprint Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901
    John D Roberts
    Virginia Commonwealth University, Richmond, Virgina 23298 0037, USA
    J Immunother 29:95-101. 2006
    ..The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2...
  2. ncbi request reprint Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage
    F Stephen Hodi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:673-8. 2006
  3. ncbi request reprint Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1857-67. 2007
    ..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)...
  4. ncbi request reprint Cytotoxic T-lymphocyte-associated antigen-4
    F Stephen Hodi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5238-42. 2007
    ....
  5. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008
    ....
  6. doi request reprint Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways
    XinQi Wu
    Department of Medical Oncology, Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 11:1905-14. 2012
    ..Targeted PKC inhibition with drugs such as AEB071 offers novel therapeutic potential for uveal melanoma harboring GNAQ mutations...
  7. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  8. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  9. pmc Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
    Jun Zhou
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Immunol Immunother 61:655-65. 2012
    ..High frequency immune responses in melanoma patients, associations with favorable treatment outcomes, and its essential role in melanoma pathogenesis support the development of ML-IAP as a disease marker and therapeutic target...
  10. doi request reprint CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
    F Stephen Hodi
    Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Nat Clin Pract Oncol 5:557-61. 2008
    ..MRI of the spine and brain revealed multiple metastases. The patient received ipilimumab and after 3 months experienced intermittent confusion and focal seizures...
  11. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
    ....
  12. doi request reprint Overcoming immunological tolerance to melanoma: Targeting CTLA-4
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Asia Pac J Clin Oncol 6:S16-23. 2010
    ..Effective anti-tumor immunity and serious autoimmunity can be disassociated. Further targeting of anti-tumor T(regs)in combinatorial therapy approaches may be a rich avenue of future investigation...
  13. ncbi request reprint Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Immun 5:7. 2005
  14. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
  15. ncbi request reprint Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
    Gerald P Linette
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, 02114, USA
    Clin Cancer Res 11:7692-9. 2005
    ..To determine the toxicity, maximal tolerated dose, and clinical and immunologic response to autologous dendritic cells pulsed with melanoma-associated antigen gp100-derived G280-9V peptide...
  16. doi request reprint The biologic importance of tumor-infiltrating lymphocytes
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
    J Cutan Pathol 37:48-53. 2010
    ..These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights...
  17. doi request reprint Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis
    Darryl A Oble
    Department of Pathology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Am J Surg Pathol 32:1130-7. 2008
    ....
  18. doi request reprint Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
    Immunol Rev 222:287-98. 2008
    ..Together, these results define key regulatory circuits that attenuate immune-mediated tumor destruction and suggest novel combinatorial therapies that might enhance the clinical activity of GM-CSF-secreting tumor cell vaccines...
  19. ncbi request reprint Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma
    Hensin Tsao
    Department of Dermatology, Massachusetts General Hospital, Boston, MA 02114, USA
    Arch Dermatol 138:799-802. 2002
    ..More recent strategies have focused on using antigen-presenting dendritic cells as vaccines...
  20. pmc Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:9190-5. 2006
    ..Moreover, these results highlight the therapeutic potential of anti-MICA antibodies to overcome immune suppression and effectuate tumor destruction in patients...
  21. ncbi request reprint Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
    Robert Soiffer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3343-50. 2003
    ..We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer...
  22. ncbi request reprint MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients
    Joseph A Mollick
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Immun 3:3. 2003
    ..These data add to the growing list of tumor antigens that appear to be translated in two frames, and suggest that OGFr and OGFr-ARF may be useful targets for vaccination...
  23. doi request reprint Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    ..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma...
  24. pmc Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
    Jan C Schmollinger
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:3398-403. 2003
    ..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape...
  25. pmc Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer
    Karen S Anderson
    Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Proteome Res 7:1490-9. 2008
    ..Here, we present the first demonstration of the application of programmable protein microarray ELISAs for the rapid identification of breast cancer autoantibodies...
  26. doi request reprint Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity
    Taylor Sittler
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Clin Cancer Res 14:3896-905. 2008
    ..We sought to identify targets of responses from this vaccination strategy...
  27. ncbi request reprint Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
    Ravi Salgia
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA
    J Clin Oncol 21:624-30. 2003
    ..To test whether this vaccination strategy enhances antitumor immunity in patients with metastatic non-small-cell lung cancer (NSCLC), we conducted a phase I clinical trial...
  28. doi request reprint Imatinib targeting of KIT-mutant oncoprotein in melanoma
    Xiaofeng Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:7726-32. 2008
    ..Biological effects of KIT inhibition in these melanomas remain poorly understood. We sought to investigate further the effects of imatinib in these melanoma subsets...
  29. pmc Modulation of T-cell activation by malignant melanoma initiating cells
    Tobias Schatton
    Transplantation Research Center, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Cancer Res 70:697-708. 2010
    ..Our findings identify novel T-cell modulatory functions of ABCB5(+) melanoma subpopulations and suggest specific roles for these MMICs in the evasion of antitumor immunity and in cancer immunotherapeutic resistance...
  30. pmc ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:6919-24. 2002
    ..Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors...
  31. ncbi request reprint Phase II study of paclitaxel and carboplatin for malignant melanoma
    F Stephen Hodi
    Adult Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Clin Oncol 25:283-6. 2002
    ..Comparisons with other treatment regimens and the search for additional active compounds against melanoma are needed...
  32. doi request reprint Major response to imatinib mesylate in KIT-mutated melanoma
    F Stephen Hodi
    The Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:2046-51. 2008
  33. ncbi request reprint Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX
    Angela M Krackhardt
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 100:2123-31. 2002
    ..These findings demonstrate that humoral and cellular immune responses against CLL-associated antigens can be detected. Ongoing experiments investigate their potential for the development of immunotherapeutic strategies...
  34. doi request reprint Modeling genomic diversity and tumor dependency in malignant melanoma
    William M Lin
    Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 68:664-73. 2008
    ..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors...
  35. ncbi request reprint High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  36. pmc Mutation-driven drug development in melanoma
    Keith T Flaherty
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Curr Opin Oncol 22:178-83. 2010
    ..The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations...
  37. ncbi request reprint Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Melanoma Res 15:77-82. 2005
    ..The demographic and survival characteristics of this MUP cohort mirrored those found in previous studies. More studies of MUP patients, as well as a standardized definition of MUP, may shed light on the pathogenesis and prognosis of MUP...
  38. ncbi request reprint Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm
    John F Thompson
    Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia
    N Engl J Med 356:285-92. 2007

Research Grants2

  1. CTLA-4 Blockade in GM-CSF Vaccinated Patients
    FRANK HODI; Fiscal Year: 2004
    ..abstract_text> ..
  2. MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION
    FRANK HODI; Fiscal Year: 2002
    ..Further identification of immunogenic antigens in melanoma offers promise for future therapies. ..